Literature DB >> 19833297

Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies.

Rocio G Urdinguio1, Jose V Sanchez-Mut, Manel Esteller.   

Abstract

Epigenetic mechanisms such as DNA methylation and modifications to histone proteins regulate high-order DNA structure and gene expression. Aberrant epigenetic mechanisms are involved in the development of many diseases, including cancer. The neurological disorder most intensely studied with regard to epigenetic changes is Rett syndrome; patients with Rett syndrome have neurodevelopmental defects associated with mutations in MeCP2, which encodes the methyl CpG binding protein 2, that binds to methylated DNA. Other mental retardation disorders are also linked to the disruption of genes involved in epigenetic mechanisms; such disorders include alpha thalassaemia/mental retardation X-linked syndrome, Rubinstein-Taybi syndrome, and Coffin-Lowry syndrome. Moreover, aberrant DNA methylation and histone modification profiles of discrete DNA sequences, and those at a genome-wide level, have just begun to be described for neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, and in other neurological disorders such as multiple sclerosis, epilepsy, and amyotrophic lateral sclerosis. In this Review, we describe epigenetic changes present in neurological diseases and discuss the therapeutic potential of epigenetic drugs, such as histone deacetylase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19833297     DOI: 10.1016/S1474-4422(09)70262-5

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  211 in total

Review 1.  Stress and the epigenetic landscape: a link to the pathobiology of human diseases?

Authors:  Sarah E Johnstone; Stephen B Baylin
Journal:  Nat Rev Genet       Date:  2010-10-05       Impact factor: 53.242

2.  Next-generation sequencing reveals regional differences of the α-synuclein methylation state independent of Lewy body disease.

Authors:  L de Boni; S Tierling; S Roeber; J Walter; A Giese; Hans A Kretzschmar
Journal:  Neuromolecular Med       Date:  2011-11-01       Impact factor: 3.843

Review 3.  Using DNA methylation to understand biological consequences of genetic variability.

Authors:  Dena G Hernandez; Andrew B Singleton
Journal:  Neurodegener Dis       Date:  2011-11-26       Impact factor: 2.977

Review 4.  Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective.

Authors:  Asfar S Azmi; Frances W J Beck; Bin Bao; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Epigenomics       Date:  2011-12       Impact factor: 4.778

5.  Two-step epigenetic Mendelian randomization: a strategy for establishing the causal role of epigenetic processes in pathways to disease.

Authors:  Caroline L Relton; George Davey Smith
Journal:  Int J Epidemiol       Date:  2012-02       Impact factor: 7.196

Review 6.  Epigenetic programming and risk: the birthplace of cardiovascular disease?

Authors:  Maria Cristina Vinci; Gianluca Polvani; Maurizio Pesce
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

Review 7.  Proteomic investigation of epigenetics in neuropsychiatric disorders: a missing link between genetics and behavior?

Authors:  Mariana D Plazas-Mayorca; Kent E Vrana
Journal:  J Proteome Res       Date:  2010-09-09       Impact factor: 4.466

Review 8.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

9.  Distinct DNA methylation changes highly correlated with chronological age in the human brain.

Authors:  Dena G Hernandez; Michael A Nalls; J Raphael Gibbs; Sampath Arepalli; Marcel van der Brug; Sean Chong; Matthew Moore; Dan L Longo; Mark R Cookson; Bryan J Traynor; Andrew B Singleton
Journal:  Hum Mol Genet       Date:  2011-01-07       Impact factor: 6.150

10.  Hypoxic adaptation engages the CBP/CREST-induced coactivator complex of Creb-HIF-1α in transactivating murine neuroblastic glucose transporter.

Authors:  Shanthie Thamotharan; Nupur Raychaudhuri; Masatoshi Tomi; Bo-Chul Shin; Sherin U Devaskar
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-01-15       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.